Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas C Turner

Showing results (81-90 of 138) with videos related to

Pageof 14
Sort By:
Molecular Oncology|January 28, 2014
TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancersBalázs Győrffy, Giulia Bottai, Jacqueline Lehmann-Che, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2022
Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline UpdateN Lynn Henry, Mark R Somerfield, Zoneddy Dayao, et al.
Science Translational Medicine|August 28, 2015
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancerIsaac Garcia-Murillas, Gaia Schiavon, Britta Weigelt, et al.
The Oncologist|June 28, 2017
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 ResultsSibylle Loibl, Nicholas C Turner, Jungsil Ro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2018
A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline <i>BRCA1/2</i> Mutations (ABRAZO)Nicholas C Turner, Melinda L Telli, Hope S Rugo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 18, 2020
<i>ESR1</i> Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT TrialsNicholas C Turner, Claire Swift, Lucy Kilburn, et al.
The Lancet. Oncology|March 8, 2016
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trialMassimo Cristofanilli, Nicholas C Turner, Igor Bondarenko, et al.
Science Translational Medicine|November 13, 2015
Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancerGaia Schiavon, Sarah Hrebien, Isaac Garcia-Murillas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast CancerCharlotte Fribbens, Ben O'Leary, Lucy Kilburn, et al.
Molecular Cancer Therapeutics|June 17, 2017
Modeling Therapy Resistance in <i>BRCA1/2</i>-Mutant CancersAmy Dréan, Chris T Williamson, Rachel Brough, et al.
Pageof 14

Showing results (81-90 of 138) with videos related to

Sort By:
Pageof 14
Molecular Oncology|January 28, 2014
TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancersBalázs Győrffy, Giulia Bottai, Jacqueline Lehmann-Che, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2022
Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline UpdateN Lynn Henry, Mark R Somerfield, Zoneddy Dayao, et al.
Science Translational Medicine|August 28, 2015
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancerIsaac Garcia-Murillas, Gaia Schiavon, Britta Weigelt, et al.
The Oncologist|June 28, 2017
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 ResultsSibylle Loibl, Nicholas C Turner, Jungsil Ro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2018
A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline <i>BRCA1/2</i> Mutations (ABRAZO)Nicholas C Turner, Melinda L Telli, Hope S Rugo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 18, 2020
<i>ESR1</i> Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT TrialsNicholas C Turner, Claire Swift, Lucy Kilburn, et al.
The Lancet. Oncology|March 8, 2016
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trialMassimo Cristofanilli, Nicholas C Turner, Igor Bondarenko, et al.
Science Translational Medicine|November 13, 2015
Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancerGaia Schiavon, Sarah Hrebien, Isaac Garcia-Murillas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast CancerCharlotte Fribbens, Ben O'Leary, Lucy Kilburn, et al.
Molecular Cancer Therapeutics|June 17, 2017
Modeling Therapy Resistance in <i>BRCA1/2</i>-Mutant CancersAmy Dréan, Chris T Williamson, Rachel Brough, et al.
Pageof 14